Related Experiment Video

Updated: Aug 15, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Structure of the cyclin-dependent kinase inhibitor p19Ink4d

F Y Luh1, S J Archer, P J Domaille

  • 1Cambridge Centre for Molecular Recognition, Department of Biochemistry, University of Cambridge, UK.

Nature
|November 14, 1997
PubMed

Insights

The structure of p19Ink4d reveals how mutations in Ink4 proteins disrupt cancer pathways. This finding aids in designing new cancer therapeutics targeting the Rb pathway.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Structural Biology

Background:

  • Cancer frequently involves disrupted tumor suppressor pathways, particularly those involving p53 and Rb.
  • The Rb pathway regulates cell cycle progression and is often altered in cancer through mutations in key proteins like Rb, cyclin D1, Cdk4, and p16Ink4a.

Purpose of the Study:

  • To determine the structure of the p19Ink4d protein using NMR spectroscopy.
  • To understand how mutations in p16Ink4a lead to loss of function.
  • To propose a model for Ink4-cyclin-Cdk interactions for therapeutic development.

Main Methods:

  • Nuclear Magnetic Resonance (NMR) spectroscopy to determine protein structure.
  • Analysis of cancer-associated mutations in p16Ink4a.
  • Structural modeling of Ink4 protein interactions.

Main Results:

  • The NMR structure of p19Ink4d was elucidated.
  • The study suggests that loss-of-function mutations in p16Ink4a often result from protein misfolding or insolubility.
  • A model for Ink4 protein interaction with cyclin-Cdk complexes was proposed.

Conclusions:

  • The determined structure of p19Ink4d provides insights into the Ink4 family of cyclin-dependent kinase inhibitors (CDKIs).
  • Understanding structural consequences of mutations is crucial for cancer therapy.
  • The proposed interaction model may guide the design of novel cancer therapeutics targeting the Rb pathway.

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach10:01

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach

Published on: June 23, 2026

Related Concept Videos

Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...